BRCA2 and breast cancer: Women who were BRCA1/BRCA2 mutation carriers and were under 45 years of age and who received risk-reducing salpingo-oophorectomy and hormonal replacement treatment did not affect their breast cancer rates (Michaelson-Cohen et al., 2021).